Literature DB >> 23769743

Peripheral 5-HT₁D and 5-HT₇ serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats.

José Ángel García-Pedraza1, Mónica García, María Luisa Martín, Jesús Gómez-Escudero, Alicia Rodríguez-Barbero, Luis San Román, Asunción Morán.   

Abstract

5-HT₂ receptor activation induces vasoconstriction, hypertension and platelet aggregation; therefore, its blocking may be useful in cardiovascular diseases, probably due to alterations in the modulation of serotonergic system. The aim of this study was to evaluate whether 5-HT₂ receptor blockade changes serotonergic modulation of sympathetic neurotransmission in pithed rats. Serotonergic modulation of sympathetic neurotransmission was investigated in Wistar rats treated with sarpogrelate, a 5-HT₂ receptor antagonist, during 14 days (30 mg/kg/day). After central nervous system destruction, we conducted electrical stimulation throughout the spinal cord flow to study the 5-HT-related products action on adrenergic system. 5-Hydroxytryptamine exerted inhibition of sympathetic outflow in sarpogrelate-treated pithed rats. This effect was mimicked and enhanced by 5-CT (5-HT₁/₇ receptor agonist). L-694,247 and AS-19, 5-HT₁D and 5-HT₇ receptor agonists respectively, reproduced this action. Pretreatment with LY310762+SB258719 (5-HT₁D and 5-HT₇ receptor antagonists, respectively) completely abolished 5-CT inhibitory action. The nature of this action was prejunctional since these agonists did not modify the pressor responses induced by exogenous noradrenaline. Western Blot analysis confirmed a higher expression of 5-HT₁D receptors in sarpogrelate-treated rats. Experimental 5-HT₂ receptor blockade induces changes in the 5-HT receptors involved in the serotonergic inhibition of sympathetic-induced pressor responses. Prejunctional activation of 5-HT₁D and 5-HT₇ receptors induces a significantly higher serotonergic inhibition on adrenergic neurotransmission in sarpogrelate-treated pithed rats. The antagonism of 5-HT₂ receptors produces an enhancement of serotonergic sympathoinhibitory effect, which may explain the beneficial effects of this blockade in cardiovascular disorders where 5-hydroxytryptamine plays a crucial role.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-CT; 5-HT; 5-HT(1D); 5-HT(2); 5-HT(7) receptors; Pithed rat; Prejunctional sympathoinhibition; Sarpogrelate

Mesh:

Substances:

Year:  2013        PMID: 23769743     DOI: 10.1016/j.ejphar.2013.05.045

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  5-Hydroxytryptamine does not reduce sympathetic nerve activity or neuroeffector function in the splanchnic circulation.

Authors:  Emma S Darios; Susan M Barman; Hakan S Orer; Shaun F Morrison; Robert P Davis; Bridget M Seitz; Robert Burnett; Stephanie W Watts
Journal:  Eur J Pharmacol       Date:  2015-02-28       Impact factor: 4.432

2.  Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.

Authors:  Jo Sourbron; Ilse Smolders; Peter de Witte; Lieven Lagae
Journal:  Front Pharmacol       Date:  2017-04-06       Impact factor: 5.810

Review 3.  Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows.

Authors:  Bruno A Marichal-Cancino; Abimael González-Hernández; Enriqueta Muñoz-Islas; Carlos M Villalón
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes.

Authors:  José-Ángel García-Pedraza; Pedro Ferreira-Santos; Rubén Aparicio; María-José Montero; Asunción Morán
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.